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EndocytosisNeuronal sphingolipids (SL) play important roles during axonal extension, neurotrophic receptor signaling and
neurotransmitter release. Many of these signaling pathways depend on the presence of specialized membrane
microdomains termed lipid rafts. Sphingomyelin (SM), one of the main raft constituents, can be formed de
novo or supplied fromexogenous sources. The present study aimed to characterize ﬂuorescently-labeled SL turn-
over in amurine neuronal cell line (CATH.a). Our results demonstrate that at 4 °C exogenously added BODIPY-SM
accumulates exclusively at the plasma membrane. Treatment of cells with bacterial sphingomyelinase (SMase)
and back-exchange experiments revealed that 55–67% of BODIPY-SM resides in the outer leaﬂet of the plasma
membrane. Endocytosis of BODIPY-SMoccurs via caveolaewith part of internalized BODIPY-ﬂuorescence ending
up in the Golgi and the ER. Following endocytosis BODIPY-SM undergoes hydrolysis, a reaction substantially
faster than BODIPY-SM synthesis from BODIPY-ceramide. RNAi demonstrated that both, acid (a)SMase and neu-
tral (n)SMases contribute to BODIPY-SM hydrolysis. Finally, high-density lipoprotein (HDL)-associated BODIPY-
SM was efﬁciently taken up by CATH.a cells. Our ﬁndings indicate that endocytosis of exogenous SM occurs
almost exclusively via caveolin-dependent pathways, that both, a- and nSMases equally contribute to neuronal
SM turnover and that HDL-like particles might represent physiological SM carriers/donors in the brain.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
Normal brain function depends on a delicately balanced set of re-
markably diverse lipids. Within the different cerebral lipid subclasses
sphingolipids (SL) take a central role in CNS and neuronal function [1].
The highly divergent group of SL is comprised of sphingosines (Sph),
ceramides (Cer), sphingomyelins (SM), and various phosphorylated
and complex glycosylated derivates [2]. SL are built of a sphingoid back-
bone, fatty acid residues (bound via an amide bond) of varying length,
and polar head groups with a wide range of complexity [3]. SL are
enriched in the CNS, where, in addition to structural roles, SL metabo-
lites act as second messengers that regulate vital signaling events
[4–6]. Therefore it is not surprising that dysfunctional SL homeostasis
is associated with neurodegenerative diseases [3,7–9].
De novo SL synthesis starts in the ER from palmitoyl CoA and ser-
ine to dihydrosphingosine that receives a fatty acid residue to formr Biology and Biochemistry,
z, Austria. Tel.: +43 316 380
attler).
. Open access under CC BY license.dihydroceramide, which is then desaturated to form Cer [6]. Cer spe-
cies are implicated in diverse cellular signaling circuits including ap-
optosis, growth inhibition, or senescence [2]. Cer is located in a
strategic position in SL metabolism [10] and is the immediate precur-
sor for SM synthesis occurring mainly in the trans-Golgi network [2].
To a lesser extent, SM synthesis proceeds at the plasma membrane
(PM) via phosphocholine transfer from phosphatidylcholine. These
reactions are catalyzed either by SM synthase (SMS)1 or SMS2 [11].
SMS1 is located exclusively to the Golgi apparatus, whereas SMS2
is present at the Golgi and the PM [11,12]. Once synthesized, the ma-
jority of SM is transported back to the PM via a vesicular transport
mechanism [13]. Like other complex SL, SM is mainly found at the
outer leaﬂet of the PM in specialized microdomains termed lipid
rafts [14]. These cholesterol- and SL-enriched microdomains are im-
portant PM platforms that compartmentalize cellular processes like
e.g. neurotrophic receptor signaling [15] or insertion of glutamate re-
ceptors [16]. Of note, SM plays a central role in Golgi vesicle formation
and subsequent cargo sorting [17], which might provide an important
transport route to dendrites of pyramidal neurons [18]. Furthermore,
in the presence of extracellular apoA-I (the major apolipoprotein of
high-density lipoprotein; HDL), cells are able to export SM via an ATP-
binding cassette transporter A1 (ABCA1)-dependent pathway. During
this efﬂux process SM is one of the lipids exportedwith highest efﬁcacy
Table 1
Solvent gradient used for elution of BODIPY-labeled lipids.
Time [min] Flow rate [ml/min] Solvent Aa [%] Solvent Bb [%] Solvent Cc [%]
5.0 0.7 80 20 0
8.0 0.7 0 100 0
11.7 0.7 0 100 0
12.0 1.0 0 100 0
15.0 1.0 0 20 80
20.0 1.0 0 20 80
20.5 1.0 80 20 0
23.0 0.7 80 20 0
a Solvent A: MeOH:H2O:Tris/HCl (0.5 M, pH 9), 93:4:3 (v/v/v).
b Solvent B: Acetonitrile.
c Solvent C: MeOH:Tris/HCl (0.5 M, pH 9), 97:3 (v/v).
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that HDL particles are important in vivo carriers of circulating SM.
In the Salvage pathway a family of sphingomyelinases (SMases)
generates phosphocholine (which is further transferred to diacylglycer-
ol) and Cer from SM. This class of enzymes is classiﬁed according to
their pH optima into acidic- (aSMase), alkaline-, and neutral (nSMase)
SMases. Currently four different nSMases that vary in subcellular local-
ization and ion dependency have been described [20]. These enzymes
play a central role in brain function since mutations or deﬁciency in
SMases leads to severe neurodegenerative disorders [4]. Hydrolysis of
Cer by ceramidases produces another bioactive lipid, Sph, which in
turn can be rapidly phosphorylated by sphingosine kinases producing
sphingosine-1-phosphate (S1P). The pathways controlling generation
of Cer, Sph and S1P have emerged as key pathways regulating the for-
mation and interconversion of these bioactive SL. Sph is a potent effec-
tor of SNARE complex assembly thereby facilitating synaptic vesicle
fusion and exocytosis [21,22].
Delicately balanced SL metabolism is necessary for neuronal
conductivity, viability, and synaptic transmission [23]. Therefore
the present in vitro study aimed to i) investigate endocytic pathways
(clathrin- and caveolae-dependent)mediating SMuptake, ii) character-
ize intracellular trafﬁcking and localization of ﬂuorescently-labeled SL
derivatives, iii) study the kinetics of SM/Cer interconversion and iv) de-
pict the contribution of SMases to Cer generation from exogenously
supplied SM in the murine CATH.a neuronal cell line.
2. Materials and methods
2.1. Materials
Cell culture supplies were from Gibco (Invitrogen, Vienna,
Austria), PAA Laboratories (Linz, Austria), Bartelt (Graz, Austria),
and Costar (Vienna). Chlorpromazine, methyl-β-cyclodextrin, genistein,
nystatin, chelerythrine chloride, nocodazole, brefeldin A, SMase from
Bacillus cereus, desipramine, and carbonyl cyanide 4-(triﬂuoromethoxy)
phenylhydrazone (FCCP) were from Sigma (Vienna). N-(4,4-diﬂuoro-
5,7-dimethyl-4-bora-3a,4a-diaza-S-indacene-3-pentanoyl)sphingosyl
phosphocholine (BODIPY FL C5-SM), N-(4,4-diﬂuoro-5,7-dimethyl-4-
bora-3a,4a-diaza-s-indacene-3-dodecanoyl) sphingosyl phosphocholine
(BODIPY FL C12-SM), N-(4,4-diﬂuoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-
indacene-3-pentanoyl) sphingosine (BODIPY FL C5-Cer = BODIPY-Cer),
LysoTracker Blue DND-22, ER-Tracker Blue-White DPX, CellMask PM
stain, 1,1′-dioctadecyl-3,3,3′,3′-tetraamethylindocarbocyanine perchlo-
rate (DiI), and HOECHST were from Molecular Probes (Invitrogen,
Vienna). Cyanine 3 monoreactive NHS ester(Cy3) was from GE
Healthcare. Polyclonal rabbit anti-scavenger receptor class B type I
(SR-BI) antibody was a kind gift from Dr. Christian Wadsack (Medi-
cal University of Graz, Austria). Horseradish peroxidase (HRP)-la-
beled secondary goat anti-rabbit IgG was from Sigma. BCA protein
assay kit and SuperSignal West Pico chemiluminescent substrate
for HRP detection were from Pierce (Thermo Scientiﬁc, Waltham,
MA, USA). GenMute siRNA transfection reagent for Neuro-2A cells
was from SignaGen laboratories (Ijamsville, MD, USA). N-[10-(1-
pyrenyl)decanoyl]-sphingosyl-1-phosphocholine (PYRENE-SM)
was synthesized according to the method described previously
[24]. siRNAs were from Qiagen (Hilden, Germany). Precision Red ad-
vanced protein assay (Reagent #2) was from Cytoskeleton (Denver,
CO, USA). All other chemicals were from Sigma, Roth (Vienna), and
Merck (Darmstadt, Germany).
2.2. Methods
2.2.1. Cell culture
Catecholaminergic CATH.a cells (ATCC, LGC Standards GmbH,Wesel,
Germany) were cultured in poly-L-lysine-coated 75 cm2 ﬂasks contain-
ing RPMI 1640 medium supplemented with 10% (v/v) horse serum(HS), 5% (v/v) fetal calf serum (FCS), 0.4% (v/v) HEPES buffer, 0.4%
(w/v) sodium pyruvate, 0.4% (w/v) L-glutamine, and 100 μg/ml
penicillin/streptomycin at 37 °C (5% CO2). The split ratio of cells
was 1:5 and only passages below 30 were used for experiments.
2.2.2. Laser scanning microscopy (LSM)
Fluorescence microscopy was performed on a Leica SP2 (Leica
Lasertechnik GmbH, Heidelberg, Germany). Excitation wavelengths for
detection of UV, green, red, and far-red ﬂuorescing compounds were
405, 488, 543, and 647 nm, respectively. Fluorescence emission was
recorded at 430–450 nm (UV), 500–535 nm (green), 555–620 nm
(red), and 665–750 nm (far-red), respectively.
2.2.3. HPLC conditions
HPLC analysis of ﬂuorescent lipids was performed using a method
that is based on the protocol ofHe et al. [25]. Lipidswere dissolved in eth-
anol and the suspension was transferred into 1.5 ml glass autosampler
vials equipped with inserts. BODIPY- and PYRENE-labeled lipids were
separated by reversed-phase HPLC (Waters HPLC 2690 Separations
Module) on a Kromasil C18 reversed-phase column (150 × 4.6 mm,
5 μm particle size; Altmann Analytik, München, Germany) equipped
with the corresponding guard column (5 × 4.6 mm, 5 μm particle size)
at a ﬂow rate of 0.7–1 ml/min. BODIPY- and PYRENE-labeled lipids
were eluted using the gradients displayed in Tables 1 and 2. A Waters
474 ﬂuorescence detector was set to 505/540 nm or 343/378 nm
(Ex/Em) to detect BODIPY- or PYRENE-labeled lipids. BODIPY-C12-
SM was used as internal standard and the product concentration
was calculated according to linear regression analysis, which was
established from standard curves of the respective ﬂuorescent lipids
(BODIPY-C5-SM, BODIPY-Cer, and PYRENE-SM, respectively).
2.2.4. Uptake studies of ﬂuorescent SM by CATH.a cells
2.2.4.1. Quantitative analyses. CATH.a cells were plated on poly-L-lysine-
coated 35 mmCulture dishes and grown to approx. 80% conﬂuence. For
steady state labeling uptake experiments, cells were incubated with
1 μM (ﬁnal concentration) BODIPY-SM, PYRENE-SM, or BODIPY-Cer in
serum-free culture medium for the indicated time periods at 37 °C in
the dark. Cells were then washed two times with ice-cold Hank's buff-
ered salt solution (HBSS), scraped in 500 μl HBSS followed by washing
the culture dish with additional 500 μl of HBSS. After centrifugation at
1500 ×g for 5 min at 4 °C the supernatant was removed and the cell
pellet was stored at−80 °C until used.
For pulse-chase experiments cells were cooled at 4 °C for 10 min.
BODIPY-SM (1 μM, ﬁnal concentration) was then added to ice-cold
serum-free culture medium and cells were pulsed for 30 min at
4 °C (to prevent endocytosis) in the dark to allow insertion of
BODIPY-SM into the PM. Following two washing steps with ice-
cold HBSS, cells were chased in serum-free culture medium for the
indicated time periods at 37 °C in the dark. Cells were then washed
two times with ice-cold HBSS, scraped, centrifuged and the cell pellet
Table 2
Solvent gradient used for elution of PYRENE-labeled lipids.
Time [min] Flow rate [ml/min] Solvent Aa [%] Solvent Bb [%] Solvent Cc [%]
5.0 0.7 0 20 80
6.0 0.7 0 100 0
7.7 0.7 0 100 0
8.0 1.0 0 100 0
10.0 1.0 40 20 40
18.5 1.0 40 20 40
21.0 0.7 40 20 40
33.0 0.7 40 20 40
33.5 0.7 0 20 80
36.0 0.7 0 20 80
a Solvent A: MeOH:Tris/HCl (0.5 M, pH 9), 99:1 (v/v).
b Solvent B: Acetonitrile.
c Solvent C: MeOH:Tris/HCl (0.5 M, pH 9), 97:3 (v/v).
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lected and lipids were extracted with 3 ml CHCl3/MeOH (2:1, v/v).
The CHCl3 phase was evaporated under a stream of nitrogen and the
dried lipid extracts were stored at−20 °C until HPLC analysis. Prior to
HPLC lipids were dissolved in 60 μl ethanol.
For lipid extraction cells were resuspended in 300 μl sterile water
(4 °C) and sonicated for 2 × 15 s on ice. The cell extracts were vortexed
vigorously and aliquots of 15 μl were taken for determination of the
protein content using the Bradford assay. One milliliter CHCl3/MeOH
(2:1, v/v) was added to the remaining cell suspension, lipids were
extracted, and the dried lipid extracts were stored at −20 °C until
HPLC analysis (lipid extracts were reconstituted in 60 μl ethanol).
When cells were labeled with PYRENE-SM lipids were dissolved in
35 μl ethanol prior to HPLC analysis.
2.2.4.2. Fluorescencemicroscopy. Cellswere grown to approx. 60% conﬂu-
ence on poly-L-lysine-coated coverslips before starting the experiments.
Pulse-chase uptake studies of BODIPY-SMwere carried out as described
above except that cells were labeled with 2 μM BODIPY-SM. After the
indicated times, cells were washed two times with ice-cold HBSS,
mounted, and analyzed by LSM. Where indicated, loosely bound ﬂuo-
rescent BODIPY-SM at the PM was removed by a back-exchange (BE)
step [26] by incubating cells with 5% fatty acid-free BSA in ice-cold
HBSS (six times for 10 min on ice). In some experiments nuclei were
counterstained with HOECHST (5 μg/ml, ﬁnal concentration) for
10 min at 37 °C before BE. Unlike otherwise noted, BODIPY-C5-SM
was used throughout all experiments and is designated as BODIPY-SM.
2.2.5. Colocalization experiments
To identify BODIPY-SM containing compartments, CATH.a cells
grown to approx. 60% conﬂuence on poly-L-lysine-coated coverslips
were incubated with speciﬁc markers for lysosomes, ER, Golgi, or the
PM, respectively. The cells were pulse-labeled with 2 μM BODIPY-SM
as described above. After washing two times with ice-cold HBSS, the
cells were chased in the presence of the lysosomal tracker Blue DND-
22 (70 nM, ﬁnal concentration) or the ER selective probe Blue-White
DPX (500 nM, ﬁnal concentration) for 30 min at 37 °C followed by a
BE of PM-bound BODIPY-SM as described above. For PM staining, the
cells were incubated in the presence of CellMask PM Stain (5 μg/ml,
ﬁnal concentration) for 5 min at 37 °C before pulse labeling with
BODIPY-SM (see above). After BE, cells were washed two times with
ice-cold HBSS, mounted, and subjected to LSM. In case of PM staining,
cells were washed two times with HBSS after pulse labeling with
BODIPY-SM and were immediately analyzed by ﬂuorescence
microscopy.
To visualize the Golgi apparatus cells were stained with BODIPY-Cer
(2 μM, ﬁnal concentration) in the same way as described for BODIPY-
SM. Pretreatment with nocodazole (30 μM, ﬁnal concentration) or
brefeldin A (20 μg/ml, ﬁnal concentration) was performed for 90 min
in serum-free culture medium at 37 °C. All subsequent incubationsteps were carried out in the presence of nocodazole or brefeldin A.
All incubation and staining steps were carried out in serum-free culture
medium in the dark.
2.2.6. Inhibition of clathrin- and caveolae-mediated endocytosis in CATH.a
cells
To clarify endocytic mechanisms BODIPY-SM uptake was qualita-
tively (LSM) and quantitatively (HPLC) analyzed in the presence of in-
hibitors that interfere with clathrin- or caveolae-mediated uptake. To
inhibit clathrin-dependent pathways, a potassium (K+) depletion pro-
tocol and chlorpromazine (CP) treatment were used. Caveolae-
mediated endocytosis was inhibited with the cholesterol depleting/se-
questering drugs methyl-β-cyclodextrin (MβCD) and nystatin (NY).
The tyrosine kinase inhibitor genistein (GE) causes local disruption of
the actin network thereby inhibiting recruitment of dynamin II [27].
Chelerythrine (CHEL) inhibits protein kinase Cα, which is present in
caveolae and required for internalization [28]. Cells grown to approx.
80% conﬂuence in poly-L-lysine-coated 6 well plates were washed
with HBSS and preincubation with inhibitors was performed as de-
scribed [26] with slightmodiﬁcations. (a) CP treatment: cells were incu-
bated in the presence of 7.5 μg/ml (ﬁnal concentration) CP for 30 min at
37 °C. (b)MβCD treatment: cellswere treatedwith 10 mg/ml (ﬁnal con-
centration) MβCD for 1 h at 37 °C to deplete PM cholesterol. (c) GE
treatment: cells were incubated in the presence of 200 μM (ﬁnal con-
centration) GE for 2 h at 37 °C. (d) NY treatment: cells were treated
with 30 μg/ml (ﬁnal concentration) NY for 30 min at 37 °C. (e) CHEL
treatment: cells were incubated in the presence of 1.5 μM (ﬁnal con-
centration) CHEL for 1 h at 37 °C. All preincubation steps were
performed in serum-free culture medium followed by pulse labeling
with 1 μM BODIPY-SM as described above in the presence of the cor-
responding inhibitors (exception: MβCD was only present during
preincubation of CATH.a cells). (f) K+ depletion: cells were washed
with K+-free buffer (20 mM HEPES, 140 mM NaCl, 1 mM CaCl2,
1 mM MgCl2, 1 mg/ml glucose, pH 7.4) and then incubated in K+-free
hypotonic buffer (K+-free buffer diluted 1:1 with distilled water) for
5 min at 37 °C. Subsequently, cells were washed two times with K+-
free buffer and incubated in the same buffer for 20 min at 37 °C before
pulse labelingwith BODIPY-SMwhichwas essentially performed in K+-
free buffer instead of serum-free culture medium. Control experiments
were done in the same way except that all buffer solutions contained
10 mM KCl.
After a 30 min chase at 37 °C cells were washed with ice-cold HBSS
and PM-bound BODIPY-SM was subjected to BE using BSA as described
above except that BE solutions contained an inhibitor cocktail (5 mM
NaN3, 50 mM 2-deoxyglucose, 2 mM iodoacetate, 10 μM FCCP; ﬁnal
concentrations) to prevent intracellular trafﬁcking. Essentially all wash-
ing and BE stepswere performed in the presence of the respective endo-
cytosis inhibitors. Following BE, cells were scraped in ice-cold HBSS as
described above and cell pellets were stored at −80 °C until lipid ex-
traction. For HPLC analysis, dried lipid extracts were dissolved in 60 μl
ethanol.
Inhibitor studies for LSMwere carried out exactly as described above
except that cells (approx. 60% conﬂuent on poly-L-lysine-coated cover-
slips) were labeled with 2 μM BODIPY-SM. LSM was performed as de-
scribed above.
2.2.7. B. cereus SMase treatment
Cells were grown in poly-L-lysine-coated 35 mm culture dishes to
approx. 80% conﬂuence. Pulse labeling with 1 μM BODIPY-SM was
performed as described above. After washing cells twice with ice-cold
HBSS cells were chased in serum-free culture medium for 1 h to ensure
equilibration of the tracer in BODIPY-SM accumulating compartments.
Cells were then washed once with HBSS containing 5% (w/v) BSA and
once with HBSS alone. Subsequently, cells were treated with bacterial
SMase (150 mU/ml, ﬁnal concentration) at 37 °C in serum-free culture
medium for the indicated time periods. Cells were washed and scraped
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until lipid extraction. For HPLC analysis, dried lipid extracts were
dissolved in 60 μl ethanol.
2.2.8. Determination of BODIPY-SM endocytosis
CATH.a cells were grown in poly-L-lysine-coated 35 mm culture
dishes to approx. 80% conﬂuence. Pulse labeling with 2 μM BODIPY-
SM was performed as described above. After washing twice with ice-
cold HBSS cells were chased in serum-free culture medium at 37 °C
for the indicated time periods. Subsequently, cells were washed with
ice-cold HBSS and BODIPY-SM was subjected to BE from the PM in
ice-cold HBSS containing 5% (w/v) BSA and an inhibitor cocktail (see
endocytosis inhibition assay) to prevent intracellular trafﬁcking
(6 × 10 min on ice). Cells were harvested by scraping in ice-cold
HBSS as described above. Cell pellets were stored at−80 °C until lipid
extraction. For HPLC analysis, dried lipid extracts were dissolved in
60 μl ethanol.
BE fractions were pooled and lipids were extracted with CHCl3/
MeOH (2:1, v/v) over night at 4 °C in the dark on a rotating wheel
followed by vortexing for 3 min. Dried lipid extracts were stored at−
20 °C until HPLC analysis for which lipids were dissolved in 500 μl eth-
anol and aliquots were transferred to inserts-containing HPLC
autosampler vials.
2.2.9. SMase assays
SMase activity in CATH.a cells was analyzed using a ﬂuorescence
assay as described [24] with some modiﬁcations. Cells (approx. 80%
conﬂuent in poly-L-lysine-coated 6 well plates) were washed twice
with ice-cold HBSS, scraped in the same buffer, and were harvested by
centrifugation as described above. The supernatant was removed and
the cells were either suspended in 100 μl acid lysis buffer (250 mM so-
dium acetate, 0.2% Triton X-100, pH 5) for analyzing aSMase activity or
in 100 μl neutral lysis buffer (20 mM HEPES, 10 mM MgCl2, 0.1 mM
Na3VO3, 0.1 mM Na2MoO4, 10 mM β-glycerophosphate, 750 μM
ATP, 2 mM EDTA, 1 mM phenylmethylsulfonyl ﬂuoride (PMSF),
20 μg/ml aprotinin, 20 μg/ml leupeptin, 0.2% Triton X-100, pH 7.4)
to measure Mg2+-dependent nSMase activity. For determinations
of Mg2+-independent nSMase activity the cells were lysed in 100 μl
neutral lysis buffer without MgCl2. The samples were sonicated in a
bath-type sonicator for 2 min (on ice) and were then incubated on ice
for 1 h (vortexing every 10 min). Cell debris were removed by centrifu-
gation (15,000 ×g, 4 °C, 10 min) and 10 μl aliquots of the supernatant
were used for determination of the protein content which was
performed in duplicates according to the Precision Red (Reagent #2)
advanced protein assay.
BODIPY-SM was used as a ﬂuorescent substrate to determine
SMase activity. BODIPY-SM (1.5 nmol in ethanol) was added per ml
acid reaction buffer (250 mM sodium acetate, 1 mM EDTA, pH 5)
under vortexing to analyze aSMase activity. Activity of nSMase was
determined in neutral reaction buffer (20 mM HEPES, 3.5 mM
MgCl2, pH 7.4) to analyze Mg2+-dependent nSMase activity. For de-
terminations of Mg2+-independent nSMase activity BODIPY-SMwas
added to neutral reaction buffer without MgCl2. Reaction buffer
(150 μl; ﬁnal substrate concentration was 1.13 μM) was transferred
into each well of a 96 well plate and 50 μl of the corresponding
lysis buffer containing 15 μg protein was added. The plate was shak-
en on a rotary shaker (1350 rpm) for 30 s and reaction was allowed
to proceed at 37 °C for 45 min in the dark. Reaction was stopped by
adding 800 μl CHCl3/MeOH (2:1, v/v) and lipids were extracted as
described above. Dried lipid extracts were stored at −20 °C until
HPLC analysis for which lipids were dissolved in 250 μl ethanol.
2.2.10. RNAi in CATH.a cells
Transfection of cells (approx. 50% conﬂuent in poly-L-lysine-coated 6
well plates)with siRNAwas performed using theGenMute siRNA trans-
fection reagent for Neuro-2A cells according to the manufacturer'ssuggestions. siRNAs used for aSMase (SMPD1), nSMase1 (SMPD2),
and nSMase2 (SMPD3) knockdown were from Qiagen (product
numbers: SI02738806 (SMPD1), SI01426971 (SMPD2_1), SI01426978
(SMPD2_2), SI01426985 (SMPD2_3), SI01426992 (SMPD2_4), and
SI01427006 (SMPD3), respectively). Concentrations of SMPD siRNA
constructs were 250 nM (SMPD1 and SMPD3 silencing) and 150 nM
(SMPD2 silencing), respectively. Forty-eight hours post transfection
the cells were subjected to analysis of SMase activity, qPCR analysis or
pulse-chase experiments, which were performed as described above.
For combined siRNA and pharmacological treatment (using the aSMase
inhibitor desipramine; Des), SMPD1-silenced cells were incubated in
the presence of Des (30 μM, ﬁnal concentration) in serum-free culture
medium for 1.5 h. All following steps were carried out in the presence
of Des.
2.2.11. RT-qPCR
Cells were transfected with speciﬁc siRNAs, lysed and RNA extracts
were collected two days post transfection. Total RNA was isolated
using the RNeasy Kit. Aliquots of total RNA (3 μg) were reverse tran-
scribed using SuperScript II Reverse Transcriptase and randomhexamer
primers according to the manufacturer's protocol (Invitrogen). Real-
time PCRs were performed with an Applied Biosystems 7900HT Fast
Real Time PCR System, the QuantiFast SYBR Green PCR kit, and
QuantiTect Primer Assays. Hypoxanthine phosphoribosyltransferase 1
(HPRT)was used as housekeeping gene. Statistical signiﬁcance of differ-
ences in mRNA expression levels was analyzed using the relative ex-
pression software tool (REST©, http://www.gene-quantiﬁcation.de/
rest.html) using a pair-wise ﬁxed reallocation test [29].
2.2.12. HDL isolation and labeling procedures
HDL was prepared by density gradient ultracentrifugation of plasma
obtained from normolipemic donors [30]. HDL was recovered from the
tubes and a desalted (PD-10 column) aliquot was used for protein de-
termination according to the Bradford assay [31]. For BODIPY-SM/DiI
co-labeling 5 nmol BODIPY-SM and 50 nmol DiI both dissolved in
DMSO were added to HDL (1 mg protein in 500 μl PBS) under
vortexing. The solution was incubated at 37 °C for 2 h in the dark
followed by gentle mixing on a rotating wheel for further 6 h at room
temperature (RT). To prepare BODIPY-SM/Cy3-labeled HDL 10 nmol
BODIPY-SM was added under vortexing. Covalent labeling of the pro-
tein moiety of HDL was performed by incubation of HDL (2 mg protein
in 1 ml 0.1 M NaHCO3, pH 8.3) with 70 nmol monofunctional Cy3 dye
dissolved in DMSO for 4 h at RT in the dark under gentlemixing on a ro-
tating wheel. Labeled HDL was desalted and separated from unbound
ﬂuorophore using a PD-10 column and PBS as eluent. After ﬁlter sterili-
zation (0.45 μm pore size) the protein concentration was determined
according to the Bradford assay. Fifty micrograms (ﬁnal concentration)
of ﬂuorescently-labeled HDL per ml serum-free culture medium was
used for steady state uptake studies. Competition experiments were
performed in the presence of a 40-fold excess of unlabeled HDL. Where
indicated, endocytosis was blocked by incubation with hypertonic su-
crose (0.4 M, ﬁnal concentration) in serum-free culture medium at
37 °C for 30 min before incubation with ﬂuorescently-labeled HDL.
For quantitative uptake studies cells were incubated in the presence
of BODIPY-SM-labeledHDL (50 μgHDL protein/ml,ﬁnal concentration).
At the indicated time points cellular lipids were extracted and analyzed
by HPLC as described above.
2.2.13. Western blot analysis of SR-BI expression
Cells (approx. 80% conﬂuent in 6 well plates) cultured in serum-
containing (15%; v/v) or serum-free medium were washed with ice-
cold PBS and then scraped in 50 μl lysis buffer (50 mM Tris/HCl, pH 7.4,
1% NP-40, 150 mM NaCl, 1 mM Na3VO4, 1 mM NaF, 1 mM EDTA,
10 μM PMSF, and 1 μg/ml each aprotinin, leupeptin, and pepstatin).
After sonication (2 × 10 s on ice) cell debris was removed by centrifuga-
tion (13,000 rpm, 4 °C, 10 min) and the protein content was determined
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reducing conditions) and transferred to PVDF membranes (150 mA).
Polyclonal rabbit anti-SR-BI antibody (1:1000)was used as primary an-
tibody. Immunoreactive bands were visualized using HRP-conjugated
goat anti-rabbit IgG (1:5000) and subsequent SuperSignal West Pico
development. Porcine brain microvascular endothelial cell protein ly-
sates served as positive control for SR-BI expression [32].3. Results
3.1. BODIPY-SM accumulates at the PM at 4 °C and is internalized at 37 °C
In a ﬁrst series of experiments time-dependent uptake and subcellu-
lar distribution of BODIPY-SM in CATH.a neurons were studied. At 4 °C
BODIPY-SM accumulated exclusively at the PM (Fig. 1A). Following re-
moval of PM-localized SM by BE to BSA and a switch to 37 °C ﬂuores-
cence was observed in punctuated intracellular structures indicative of
early recycling endosomes (Fig. 1B). At later time points (15–240 min;
Fig. 1C–F) BODIPY-ﬂuorescence is primarily localized at the ER and/or
perinuclear regions resembling the Golgi apparatus.
To elucidate intracellular localization of BODIPY-SM/Cer in more de-
tail, colocalization experiments with organelle-selective probes were
performed. First, colocalization of CellMask PM stain (red) and
BODIPY-SM (green) was conﬁrmed at 4 °C (Fig. 2A). Under the experi-
mental conditions applied, part of the PM marker was subject to inter-
nalization. At 37 °C partial colocalization of the ER tracker (red) and
BODIPY-ﬂuorescence (green) was observed (Fig. 2B), while almost no
colocalization of the LysoTracker (blue) with BODIPY-SM (green) was
detectable (Fig. 2C). Labeling of cells with the Golgi marker BODIPY-
C5-Cer resulted in an identical ﬂuorescence pattern as observed with
BODIPY-SM (Fig. 2D, a). Pretreatment of cells with the microtubule-
disrupting agent nocodazole resulted in accumulation of BODIPY-SM
in intracellular punctuate structures (Fig. 2D, b). These ministacks ap-
parently result fromGolgi fragmentation due to disruption of themicro-
tubular network. Brefeldin A treatment resulted in PM-associated asFig. 1. Uptake and subcellular localization studies of ﬂuorescent BODIPY-SM. CATH.a cells were
culturemedium for 30 min at 4 °C. Cells werewashedwithHBSS and chased for (A) 0 min, (B)
at the PM was removed by BE prior to LSM analysis (B-F). Nuclei in (F) were counterstained wwell as diffuse intracellular ﬂuorescence, most probably a consequence
of BODIPY-SM trapping in an ER-Golgi hybrid compartment (Fig. 2D, c).
3.2. Initial pathways of BODIPY-SM endocytosis and turnover in CATH.a
neurons
Endocytosis of BODIPY-SM uptake was followed on a qualitative
(LSM) and quantitative basis (HPLC). Cells were preincubated in the ab-
sence or presence of the respective inhibitors at the indicated concen-
trations before pulse labeling with BODIPY-SM at 4 °C followed by a
30 min chase at 37 °C. Control cells accumulated the label in perinuclear
regions and this pattern was not signiﬁcantly altered in response to CP
treatment or K+ depletion (Fig. 3). In contrast, inhibitors of caveolae-
dependent endocytosis (MβCD, NY, GE, and CHEL) resulted in lower
ﬂuorescence intensity in intracellular compartments. These data sug-
gest that NY (followed by GE, CHEL, and MβCD) inhibited BODIPY-SM
uptake with highest efﬁcacy indicating that the majority of BODIPY-
SM is internalized via caveolae-mediated pathways.
To quantitatively conﬁrm results obtained by ﬂuorescence microsco-
py CATH.a cellswere pretreatedwith the respective inhibitors and pulse-
labeled with BODIPY-SM. Cellular lipids were extracted and analyzed by
HPLC. In line with LSM data, CP treatment and K+ depletion were with-
out effect on BODIPY-SM uptake (Fig. 4). In contrast, MβCD, NY, GE, and
CHEL inhibited BODIPY-SM uptake by 30, 80, 60, and 40%, respectively.
Having established caveolae-mediated uptake as themajor pathway
of BODIPY-SM internalization we next investigated intracellular
BODIPY-SM hydrolysis to BODIPY-Cer, the ﬁrst metabolic step in SM re-
modeling. During these studieswe utilized steady state and pulse-chase
labeling protocols. To exclude artifacts due to the ﬂuorophore two dif-
ferent ﬂuorescently-labeled SM derivatives were used. During steady
state labeling (providing a continuous tracer supply), cells were incu-
bated with BODIPY-SM, PYRENE-SM, or BODIPY-Cer, followed by HPLC
analyses of cellular lipids. These experiments revealed that BODIPY-
SM hydrolysis is a relatively fast process with BODIPY-Cer generation
being detectable already after 5 min (Fig. 5A). BODIPY-SM levels in
CATH.a cells peaked after 1 h (850 pmol/mg cell protein) and declinedcooled at 4 °C for 10 min and then pulse-labeled with BODIPY-SM (2 μM) in serum-free
5 min, (C) 15 min, (D) 30 min, (E) 60 min, or (F) 240 min at 37 °C. Remaining BODIPY-SM
ith HOECHST (5 μg/ml) for 10 min at 37 °C.
b ca
A
B
C
D
Tracker BODIPY-SM Merge
Fig. 2. Colocalization of BODIPY-SM with organelle-speciﬁc markers. CATH.a cells were cooled at 4 °C for 10 min and then pulse-labeled with BODIPY-SM (2 μM) in serum-free culture
medium for 30 min at 4 °C. Cells were stained with (A) CellMask PM stain (5 μg/ml) or were chased for 30 min at 37 °C in the presence of (B) ER-Tracker Blue-White DPX (500 nM)
or (C) LysoTracker Blue DND-22 (70 nM). Cells were washed and subjected to BE (B and C). (D) Cells were stained with BODIPY-Cer (2 μM; a) in the same way as described for
BODIPY-SM, or pre-incubated with nocodazole (30 μM; b) or brefeldin A (20 μg/ml; c) for 90 min at 37 °C and then pulse-chase-labeled with BODIPY-SM as described above.
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BODIPY-Cer generation occurred at similar rates as observed for SM ac-
cumulation (up to 60 min) and showed highest intracellular concen-
trations after 4 h of incubation (690 pmol/mg cell protein). Starting
from this time point BODIPY-Cer concentrations slightly exceeded
the concentrations of cell-associated BODIPY-SM (up to 1.3-fold).
Uptake of PYRENE-labeled SM(carrying a C10-acyl residue thatmore
closely resembles physiochemical properties of natural SM) is almost
one order of magnitude lower (Fig. 5B) as compared to the BODIPY-
labeled analog. PYRENE-SM hydrolysis was less efﬁcient as compared
to BODIPY-SM since only 16% of total cell-associated PYRENE ﬂuores-
cence was converted to PYRENE-Cer after a 24 h steady state labeling
experiment.
Next we were interested in the efﬁcacy of BODIPY-SM synthesis
from BODIPY-Cer. These data suggest that BODIPY-SM synthesis from
BODIPY-Cer is a slower process than BODIPY-SM hydrolysis, reaching
a plateau after 4 h (Fig. 5C) where BODIPY-Cer levels still exceed the
levels of generated BODIPY-SM up to 2.4-fold.To get an indication about the time-dependent metabolism of a de-
ﬁned concentration of PM-located BODIPY-SM in CATH.a cells, we have
performed pulse-chase studies and subsequent HPLC analyses of cell
and medium lipids. As shown in Fig. 6A cells contained 28 pmol
BODIPY-SM and 7 pmol BODIPY-Cer at time zero (indicating partial hy-
drolysis already at 4 °C). After 24 h cells contained 4 and 6 pmol
BODIPY-SM and BODIPY-Cer, respectively, indicating a total loss of
25 pmol cell-associated BODIPY lipids. This loss of cellular lipidswas ac-
companied by a gain in the cellular supernatant containing (after 24 h)
7 pmol BODIPY-SM, 7 pmol BODIPY-Cer, and 15 pmol of a currently
unidentiﬁed BODIPY-containing lipid (termed BODIPY-SL; Fig. 6B) indi-
cating efﬁcient efﬂux of BODIPY-labeled SL to the cellular supernatant.
3.3. Quantitation of PM-located BODIPY-SM
PM-located SM is rapidly metabolized (Fig. 6A), resulting in the gen-
eration of Cer (Figs. 5A and 6A), Sph, or S1P [33]. To quantitate the
amount of SM residing in the PM of CATH.a neurons two experimental
CP
NY CHELMβCD GE
+ K+ - K+control
Fig. 3. Inhibition of BODIPY-SM endocytosis by pharmacological antagonists. To inhibit clathrin-mediated endocytosis, CATH.a cells were incubated in the absence (control) or presence of
chlorpromazine (CP; 7.5 μg/ml; 30 min) or were incubated in the presence (+K+) or absence (−K+) of potassium. K+ depletion was performed by treatment with K+-free hypotonic
buffer (control cells (+K+) were treated with hypotonic buffer containing 10 mM KCl). To interfere with caveolar uptake, cells were preincubated in the absence (control) or presence
of methyl-β-cyclodextrin (MβCD; 10 mg/ml; 60 min), nystatin (NY; 30 μg/ml; 30 min), genistein (GE; 200 μM; 120 min), or chelerythrine (CHEL; 1.5 μM; 60 min) at 37 °C. Following
inhibitor treatment cells were washed with ice-cold HBSS and cooled at 4 °C for 10 min, followed by pulse labelingwith BODIPY-SM (2 μM) in serum-free culturemedium or the respec-
tive K+-free/K+-containing buffers for 30 min at 4 °C. Cells were washed with HBSS and chased for 30 min. After removal of membrane-bound BODIPY-SM by BE cells were subjected to
LSM analysis. All incubation steps were performed in the presence of the inhibitors except for MβCD, which was present only during the preincubation period. All micrographs were
recorded with the same laser intensity.
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to hydrolysis by exogenously added B. cereus SMase. Following pulse la-
beling at 4 °C and a 60 min chase period (37 °C) cells contained 55 and
61 pmol/mg cell protein of BODIPY-SM and BODIPY-Cer, respectively
at time zero. Treatment with B. cereus SMase reduced the BODIPY-SM
concentrations to 17 pmol/mg cell protein, indicating that 67% are acces-
sible to B. cereus SMase-mediated hydrolysis (Fig. 7A). Cellular BODIPY-
Cer concentrations transiently increased from 61 to 97 pmol/mg cell
protein after 15 min of B. cereus SMase treatment. Then, concentrations
decreased, reaching a plateau after further 45 min (≈65 pmol/mg cell
protein). This might be a result of Cer efﬂux to the cellular supernatant
and/or Cer conversion to other, more complex SL species.Fig. 4. Quantitation of BODIPY-SM endocytosis in the presence of pharmacological antag-
onists. CATH.a cellswere incubatedwith BODIPY-SM(1 μM)and the corresponding inhib-
itors as described in Fig. 3. Cells were scraped in ice-cold HBSS and lipids were extracted
with CHCl3/MeOH. Dried lipids were re-dissolved in ethanol and analyzed by HPLC. Re-
sults are expressed as ﬂuorescence intensity as % of control and represent mean ± SD
(n = 3) of one representative experiment. ***p b 0.001 (in comparison to controls, ‘C’).In a second approach cells were pulse-labeled with BODIPY-SM
and then switched to 37 °C to allow internalization. At the indicated
times cells were washed and PM-located BODIPY-SM was removed
by BE at 4 °C. BODIPY-SM and BODIPY-Cer were quantitated in the
BE medium and in cellular lipid extracts (Fig. 7B). Results of these
studies revealed that at time zero the majority (92%) of BODIPY-SM
was located in the PM (i.e. accessible to BE). After 2 h, 55 and 11%
of total ﬂuorescence was recovered as BODIPY-SM and BODIPY-Cer
in the BE medium (i.e. PM-associated). The cellular lipid extracts
contained 13 and 21% of total ﬂuorescence (BODIPY-SM and
BODIPY-Cer), respectively. In summary these experiments indicate
that approx. 55 (accessible to BE) to 67% (accessible to B. cereus
SMase) of BODIPY-SM is located in the outer leaﬂet of the PM.3.4. Contribution of neuronal SMases to BODIPY-SM hydrolysis
Findings shown in Figs. 5–7 demonstrate that endogenous SMases
are responsible for SMhydrolysis in CATH.a cells. Expression analysis re-
vealed that the three different SMases, aSMase (gene symbol SMPD1),
nSMase1 (SMPD2), and nSMase2 (SMPD3), are present at similar ex-
pression levels in CATH.a cells (Fig. 8A). Next we tested whether
SMase mRNA expression is reﬂected on activity level. Indeed we have
observed nearly identical aSMase and nSMase activity (BODIPY-SM
conversion rates approx. 65 pmol/min/mg cell protein, data in good
agreementwith another report; [34]). In contrast to aSMase, nSMase ac-
tivity strongly depends on the presence of Mg2+ (Fig. 8B).
To identify the SMase(s) that are responsible for SM hydrolysis,
we applied a siRNA strategy. qPCR analyses of silenced cells re-
vealed downregulation of mRNA levels by 57, 77, and 60%
(SMPD1–3; Fig. 8C). While SMPD1 and -3 silencing did not impact
on transcript levels of non-targeted SMases, silencing of SMPD2 in-
duced downregulation of SMPD1 by approx. 40%. To address this issue
Fig. 5.Uptake andmetabolism of ﬂuorescent SMand Cer analogs during steady state labeling. CATH.a cellswere incubatedwith (A) BODIPY-SM, (B) PYRENE-SM, or (C) BODIPY-Cer (1 μM
each) for the indicated time periods at 37 °C. Cells were washed with HBSS, scraped, and cellular lipids were extracted with CHCl3/MeOH, dried, dissolved in ethanol, and analyzed by
HPLC. Results shown represent mean values from one representative experiment performed in duplicates.
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sion. Results of these analyses (Fig. 8D) revealed that this effect appears
to be speciﬁc for siSMPD2_3 indicating an off-target effect of this partic-
ular siRNA rather than a general counter-regulation of SMPD1 and -3 in
response to knockdown of SMPD2.
Silencing of SMPD1 attenuated aSMase activity in cell lysates by 60%
and SMPD2 silencing reduced aSMase activity by 37% (Fig. 8E). This off-
target effect of siSMPD2_3 on aSMase activity is in line with qPCR data
shown in Fig. 8C and D. Silencing of SMPD2 or SMPD3 inhibited nSMase
activity by 35 and 25%, respectively. Co-silencing of both nSMases re-
duced enzyme activity by 55% (Fig. 8F).
Finally we have established the effect of SMase silencing on BODIPY-
SM to BODIPY-Cer conversion in intact cells. Forty-eight hours post-
transfection cells were pulse-labeled with BODIPY-SM followed by
HPLC analysis of BODIPY-SM and BODIPY-Cer of cellular lipid extracts.
Knockdown of SMPD1 reduced BODIPY-Cer generation by 20% and
this effect was enhanced to 28% in the presence of the lysosomotropic
agent Des (Fig. 8G). Knockdown of SMPD2 or SMPD3 or in combination
attenuated BODIPY-Cer levels by 25, 33, and 42% after 30 min. A family
knockdown including SMPD1–3 reduced cellular BODIPY-Cer concen-
trations by 68%.
3.5. Uptake of HDL-associated BODIPY-SM
In the brain SM is most likely transported in association with apoE/
A-I-containing HDL-like particles [35] and HDL-associated lipids are
subject to holoparticle and/or selective uptake via initial interaction of
apoA-I with SR-BI [36]. First we showed that SR-BI expression levels
are not regulated by the serum content of the culture medium (Fig. 9A).
LSM analyses of CATH.a cells incubated with BODIPY-SM (green)
and DiI (red; a surrogate tracer for selective uptake of HDL-associated
lipids; [37]) -labeled HDL demonstrate that the majority of originallyHDL-associated BODIPY-SM remains at the PM at early time points
(Fig. 9B, a). At time points ≥60 min BODIPY-SM started also to ac-
cumulate in intracellular compartments and in some (but not all)
cells colocalizes with DiI (yellow; Fig. 9B, b and c). In contrast to
BODIPY-SM, DiI staining occurred in a more punctuate staining
pattern probably resembling endocytic compartments. An excess
of unlabeled HDL efﬁciently competed for uptake of BODIPY-SM/
DiI-labeled HDL (Fig. 9B, d). Pre-treatment with hypertonic sucrose
(inducing an endocytic block; [37]) resulted in partial but not com-
plete inhibition of BODIPY- and DiI uptake (Fig. 9B, e). In addition,
PM localization of BODIPY-SM changed to diffuse intracellular
staining. Taken together, these results indicate that internalization
of the majority of ﬂuorescently-labeled HDL is mediated apparently
by SR-BI-dependent endocytosis.
HDL covalently labeled with Cy3 in the protein moiety showed a
more pronounced staining (Fig. 9C) as compared to DiI-labeled HDL.
Of note, Cy3-labeled HDL uptake is a fast process with tracer accumula-
tion in intracellular compartments already visible after 5 min (Fig. 9C,
a). Whereas intracellular localization of Cy3 ﬂuorescence remained
more or less unaffected during the entire incubation period, BODIPY-
SM localized almost exclusively to the PM after a 5 min chase at 37 °C
(Fig. 9C, a) and started to accumulate in perinuclear regions at time
points ≥60 min where it partially colocalizes with the Cy3-labeled
HDL protein moiety (Fig. 9C, b and c). Both an excess of unlabeled
HDL and hypertonic sucrose treatment strongly reduced BODIPY-SM
and Cy3 staining (Fig. 9C, d and e). Taken together, these results indicate
that BODIPY-SM uptake is less affected by hypertonic sucrose as com-
pared to DiI- and Cy3-HDL uptake.
Quantitation of BODIPY-SL in CATH.a cells incubated with BODIPY-
SM-labeled HDL revealed saturable uptake kinetics. Cell-associated SM
levels reached a maximum concentration of 20 pmol/mg cell protein
(4 h; Fig. 9D). However, compared to carrier-free BODIPY-SM, hydrolysis
Fig. 6. Turnover of BODIPY-SM after pulse labeling. CATH.a cells were cooled at 4 °C for
10 min, pulse-labeled with BODIPY-SM (1 μM) in serum-free culture medium for
30 min at 4 °C, washed, and chased for the indicated time periods at 37 °C. Cells were
washedwithHBSS, scraped, followed by lipid extraction from (A) cells and (B) the cellular
supernatant. Lipid extracts were subjected to HPLC analysis. Results shown represent
mean values from one representative experiment performed in duplicates.
Fig. 7.Analysis of PM-located BODIPY-SM. CATH.a cells were cooled at 4 °C for 10 min and
pulse-labeled with BODIPY-SM (1 μM for B. cereus SMase treatment and 2 μM for the BE
protocol) in serum-free culture medium for 30 min at 4 °C. (A) Cells were washed and
chased in serum-free culture medium at 37 °C for 60 min to enable BODIPY-SM internal-
ization. Cells were then subjected to B. cereus SMase treatment (150 mU/ml) in serum-
free culture medium at 37 °C up to 4 h. Cellular lipid extracts were analyzed by HPLC.
(B) After pulse labeling cells were washed and chased at 37 °C. At the indicated times
cells were subjected to BE at 4 °C followed by BODIPY-SL analysis in the BE fractions and
cell extracts by HPLC. Results shown represent mean values from one representative ex-
periment performed in duplicates.
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exceed that of BODIPY-SM.
4. Discussion
Here we present evidence that internalization of BODIPY-SM by the
murine CATH.a neuronal cell line is energy-dependent and primarily
mediated by caveolar mechanisms. BODIPY-SM (or BODIPY-Cer gener-
ated from the probe) is not delivered to lysosomes but is transported
to the ER/Golgi complex, probably via recycling endosomes. Cer gener-
ation from SM is more efﬁcient than SM synthesis from Cer indicating
high SMase and lower SMS activity. Since a major fraction of SM resides
in the PM it is conceivable that SMase-mediated hydrolysis of BODIPY-
SM starts already in this compartment. Pharmacological inhibition and
RNAi experiments suggest that both aSMase and nSMases contribute
to SM hydrolysis.
Steady state and pulse-chase labeling experiments revealed that at
4 °C BODIPY-SM accumulates in the PM of CATH.a neurons. A switch to
37 °C results in the occurrence of ﬂuorescent punctuate structures indi-
cating vesicle mediated transport with the tracer ﬁnally ending up in the
Golgi (Fig. 1). This parallels previous studieswhere ﬂuorescently-labeled
SM analogs were observed in these compartments after a short incuba-
tion period at 37 °C [26,38,39]. Babia et al. [40] demonstrated that inter-
nalization of NBD-SMwas energy- and temperature-dependent, and that
intracellular transportwas insensitive to theNBD-ﬂuorescence quencher
sodium dithionite. These results indicate that vesicles mediate the trans-
port of internalized NBD-glucosylceramide (NBD-GlcCer) and NBD-sphingomyelin to the Golgi complex [40]. The same authors have dem-
onstrated that only a small fraction of NBD-SM in the PM is subjected
to hydrolysis to Cer while internalized NBD-SM remained unaltered
in primary rat hippocampal neurons. This contrasts with our ﬁndings
in the murine CATH.a cell line, where a substantial fraction of
BODIPY-SM was hydrolyzed to BODIPY-Cer independent whether a
steady state or pulse-chase labeling protocol was used (Figs. 5 and
6). Therefore it is likely that BODIPY-Cer provides a signiﬁcant con-
tribution to Golgi ﬂuorescence (Fig. 2). In addition to the Golgi we
have also observed accumulation of BODIPY-tagged lipids in the ER.
Galactosylceramide (GalCer) and, unlike to other cells, GlcCer syn-
thesis in neurons takes place in the ER [41]. This raises the possibility
that BODIPY-Cer generated via SMase activity reaches the ER, and
serves as precursor for GlcCer and/or GalCer synthesis. However,
these issues were not addressed during the present study. In line
with other groups [39,42] we have been unable to detect
ﬂuorescently-labeled SM in lysosomes.
There is limited informationon themechanismsof SM internalization
from the PM and subsequent intracellular targeting. Most of the data are
based on studieswithﬂuorescently-labeled SM.NBD-SM incorporated in
the PM is endocytosed and rapidly sorted for recycling to the PM [43]
whereas BODIPY-SM predominantly labels the Golgi [26]. Golgi labeling
may be due to vesicular transport of BODIPY-SM from endosomes to the
Golgi and/or hydrolysis of BODIPY-SM to the corresponding BODIPY-Cer,
which has a high afﬁnity for the Golgi [44]. Endocytic trafﬁcking of
Fig. 8. Contribution of individual SMases to BODIPY-SM hydrolysis. (A) SMase expression by CATH.a cells grown under standard conditions was analyzed by RT-qPCR using
validated primers for aSMase (SMPD1), nSMase1 (SMPD2), and nSMase2 (SMPD3). Target gene expression is expressed in relation to hypoxanthine-guanine
phosphoribosyltransferase (HPRT). Gene expression was calculated by REST analysis as described in Materials and methods. (B) Cells were lysed in lysis buffer under acidic
(aSMase activity) or neutral (nSMase activity) conditions and SMase activity of cell lysates was determined as described in Materials and methods. (C) Impact of targeted
SMase silencing on transcript expression of nontargeted members. RT-qPCR analyses were performed 48 h post transfection with the indicated siRNAs. Results are expressed
as relative expression levels (target gene/HPRT) using REST analysis. (D) Effects of different SMPD2 siRNAs on SMPD1-3 mRNA expression. Silencing was performed with
four different 21-mer siRNAs. RT-qPCR analyses were performed 48 h post transfection with the indicated siRNAs. Results are expressed as relative expression levels (target
gene/HPRT) using REST analysis. (E, F) Impact of SMase silencing on aSMase (E) and nSMase (F) activity of CATH.a cell lysates. Cells were either untransfected (‘C’), mock
transfected, or transfected with the indicated siRNAs. Enzyme activities were determined 48 h post silencing of the indicated target SMase(s). Results represent mean ± SD
(n = 3) of one representative experiment. ***p b 0.001 (in comparison to controls). (G) Impact of SMase silencing on BODIPY-SM hydrolysis by intact CATH.a cells. SMase
expression was silenced with siRNAs. Forty eight hours post transfection cells were pulse-labeled with BODIPY-SM (1 μM) at 4 °C and chased for 10 and 30 min at 37 °C.
Cellular lipids were extracted and BODIPY-SM and BODIPY-Cer concentrations were analyzed by HPLC. Desipramine (Des; 30 μM) treatment of SMPD1-silenced cells was
performed for 1.5 h prior BODIPY-SM labeling to enable maximal suppression of BODIPY-SM hydrolysis by aSMase. Results represent the BODIPY-Cer contents in transfected
cells normalized to BODIPY-Cer concentrations measured in non-transfected cells (% of controls) and represent mean ± SD (n = 3) of one representative experiment.
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recycle more effectively to the PM while long-chain SM are
transported along the late endocytic pathway and recycle in an
NPC1- and cholesterol-dependent manner. Puri et al. [26] have dem-
onstrated that different SL are internalized via different endocytic
pathways. While lactosylceramide (LacCer) and globoside are internal-
ized almost exclusively via caveolar pathways, BODIPY-SM uptake was
mediated to equal parts by clathrin- and caveolae-dependent pathways
[26]. Caveolar SL internalization in ﬁbroblasts occurs along microtu-
bules (as observed during the present study; Fig. 2D, b) and depends
on phosphoinositol 3-kinases and rab proteins [45]. To elucidate uptake
mechanisms for BODIPY-SM in CATH.a cells inhibitors of clathrin- andFig. 9.Uptake of HDL-associated BODIPY-SM. (A) Protein lysates obtained from porcine brainmic
the absence (lane 2) or presence (lane 3) of serum were separated on 10% SDS gels and transfe
Immunoreactive bands were detected at an apparentmolecular weight of approx. 80 and 160 kD
pertonic sucrose (e) for 30 min followed by addition of BODIPY-SM/DiI-labeledHDL (50 μgHDL p
40-fold excess of unlabeled HDL. After washing with HBSS cells were subjected to LSM analysis
serum-free medium (a–d) or in the presence of hypertonic sucrose (e) for 30 min followed by
e) 60 min, or (c) 240 min at 37 °C. Cells in (d) received a 40-fold excess of unlabeled HDL. Afte
with the same laser intensity. (D) Cells were incubated with BODIPY-SM-labeled HDL (50 μg H
ethanol, and analyzed by HPLC. Results shown represent mean values from one representative ecaveolae-mediated endocytosis were tested (Figs. 3 and 4). Pronounced
inhibition of BODIPY-SMuptake by antagonists of the caveolar pathway
strongly suggests that this is quantitatively themore important route in
CATH.a neurons. Endocytic pathways of ﬂuorescently-labeled SM ana-
logs are somewhat controversial. Whereas some groups suggested SM
uptake in clathrin-coated pits and caveolae [26], other studies highlight
SM stereochemistry as a major determinant which endocytic pathway
is chosen: Naturally occurring BODIPY-D-erythro-SM (as used during
the present study) is internalized via a NY-sensitive, CP-insensitive
mechanism in human skin ﬁbroblasts, whereas BODIPY-L-threo-SM is
taken up via a CP-sensitive mechanism, similar to what was observed
with stereoisomers of BODIPY-labeled LacCer [46,47].rovascular endothelial cells (positive control; lane 1) and CATH.a cells incubated for 24 h in
rred to PVDF membranes for subsequent detection using anti-SR-BI as a primary antibody.
a (arrows). (B) Cells were incubated in serum-freemedium (a–d) or in the presence of hy-
rotein/ml) for (a) 5 min, (b, d, and e) 60 min, or (c) 240 min at 37 °C. Cells in (d) received a
. All micrographs were recorded with the same laser intensity. (C) Cells were incubated in
addition of BODIPY-SM/Cy3-labeled HDL (50 μg HDL protein/ml) for (a) 5 min, (b, d, and
r washing with HBSS cells were subjected to LSM analysis. All micrographs were recorded
DL protein/ml) for the indicated times at 37 °C. Cellular lipids were extracted, dissolved in
xperiment performed in duplicates.
Fig. 9 (continued).
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cytotic processes have been reported: Zha et al. [48] demonstrated that
treatment of ATP-depleted macrophages and ﬁbroblasts with exoge-
nous SMase rapidly induces formation of numerous vesicles that pinch
off from the PM. These authors [48] concluded that hydrolysis of SM
on the PM causes inward curvature and subsequent fusion to form
sealed vesicles that lack a caveolin or clathrin coat. These ﬁndings sug-
gest that (at least some) mammalian cells use SMase to change lipid
composition locally thereby promoting membrane budding and fusion.
Of note, comparable observations were reported for SMase-treated
protein-free giant vesicles composed of PC, SM, and BODIPY-SM
[49,50]. The authors demonstrated that SMase added to the outside of
SM-containing giant vesicles results in an endocytosis-like process solely
dependent on newly formed Cer-enriched microdomains [49]. This pro-
cess involves SMase-mediated Cer formation in the outer leaﬂet, lateralphase separation of Cer-enriched domains, invagination, budding, and ﬁ-
nally ‘endocytosis’ of these vesicles into the giant vesicles. In contrast,mi-
croinjection of SMase into the interior of giant vesicles (leading to SM
hydrolysis at the inner leaﬂet) resulted in liposome formation on the
outer leaﬂet [49]. Collectively these ﬁndings suggest that membrane en-
docytosis or blebbing (depending on whether Cer is formed at the outer
or inner leaﬂet of themembrane)might be driven by Cer formation inde-
pendent of metabolic energy and a caveolin- or clathrin coat.
Steady state labeling of CATH.a cells revealed lower uptake kinetics
(probably due to the lack of the polar phosphocholine headgroup) of
BODIPY-Cer compared to BODIPY-SM (Fig. 5). Also PYRENE-SM uptake
was slower as compared to the corresponding BODIPY analog most
probably a result of the higher hydrophobicity of the PYRENE tag.
These results indicate different, ﬂuorophore-dependent uptake proper-
ties (see also above) of tagged lipids and their speciﬁc (dis)advantages
1677C. Nusshold et al. / Biochimica et Biophysica Acta 1831 (2013) 1665–1678with regard to partitioning into ordered domains of the PM have been
addressed [51,52].
Of note, SMases display similar enzyme afﬁnity for NBD- or BODIPY-
SM as compared to their natural counterparts [24,53]. Our pulse-chase
studies (Fig. 7) demonstrated that BODIPY-SM uptake and metabolic
conversion of the tracer occur rapidly. The preference of neurons for
SM hydrolysis over SM synthesis is supported by studies that showed
rapid NBD-SM hydrolysis in neurons and slow conversion of NBD-Cer
to NBD-SM while the opposite is true for oligodendrocytes [54].
Although increased intracellular Cer concentrations are considered pro-
apoptotic [55], SMase-mediated Cer synthesis could fuel a ceramidase-
dependent [56], Sph-generating pathway that is centrally involved in
SNARE assembly and synaptic vesicle fusion [21,22]. A signiﬁcant frac-
tion of BODIPY-SM was already metabolized after pulse labeling at
4 °C. This suggests that SMases are enzymatically active even at low tem-
peratures, which is in line with others [57,58]. Interestingly a quantita-
tively signiﬁcant proportion of BODIPY-SM and BODIPY-Cer as well as
an unidentiﬁed BODIPY-SLwere recovered from the cellular supernatant
(Fig. 6B). Using two different experimental approaches (Fig. 7) we
could show that a major fraction of exogenously supplied BODIPY-
SM is localized in the PM where it would be accessible to SMases.
Whether the presence of BODIPY-labeled SL in the supernatant is a
result of synthesis/release from the outer leaﬂet of the PM or due
to active efﬂux is currently under investigation.
Using siRNAs and pharmacological inhibition our results suggest
that aSMase as well as nSMases contribute to BODIPY-SM hydrolysis
(Fig. 8). This is in line with our observation of almost identical activities
of aSMase and Mg2+-dependent nSMase in CATH.a cell lysates. Despite
the absence of BODIPY-SM colocalization with the LysoTracker (Fig. 2C)
BODIPY-SM hydrolysis could occur at the PM, where a substantial pro-
portion of aSMase is localized [59–61]. Also nSMase(s) have been
shown to localize at the PM and palmitoylation was reported to facili-
tate nSMase2 localization at the cytosolic face of the PM [62]. Whether
nSMase-mediated hydrolysis of SM at the PM (as shown for exogenous-
ly added nSMase in hippocampal neurons; [63]) contributes to the gen-
eration of S1P at the PM remains to be elucidated. Studies in PC12 cells
demonstrated localization of nSMase to the Golgi [64], supporting the
idea that part of BODIPY-SM is hydrolyzed at this organelle. Additional-
ly, recent studies have shown that nSMase can translocate from the PM
or the Golgi to early endosomes [33]. These ﬁndings implicate that
nSMase activity could contribute to BODIPY-SM hydrolysis in several
subcellular compartments.
Findings of the present study indicate that HDL could act as phys-
iological carrier and donor of SM. HDL lipids are taken up by cells/
tissues either through HDL holoparticle internalization or endocytosis-
dependent [65] or -independent [37] selective uptake via SR-BI. Along
this line it is important that selective uptake of HDL-associated SM is
mediated by SR-BI and depends on intact caveolae [66]. In the CNS de-
livery of SM via apoE-containing, reconstituted HDL particles stimulates
axonal extension, indicating a potential involvement of HDL-associated
SM in nerve regeneration [67]. The authors of that study [67] also dem-
onstrated that this process requires LDL receptor-related protein-1 indi-
cating that this receptormediates neuronal holoparticle uptake of apoE-
containing lipoproteins.
On basis of competition and hypertonic sucrose inhibition experiments
the present study indicates that BODIPY-SMuptake occurs primarily via
endocytic pathways. In line, HDL particles were shown to undergo en-
docytosis, lose lipids, followed by resecretion of lipid-depleted particles
by non-polarized hepatocytes [68]. In polarized hepatocytes HDL parti-
cles enter the endocytic recycling compartment paralleling intracellular
trafﬁcking of SR-BI [65]. Data obtained during the present study where
sucrose inhibited the uptake of all ﬂuorescent, HDL-associated tracers
(independent whether bound covalently or non-covalently) would
support an uptake mechanism of HDL-associated BODIPY-SM that is
coupled to endocytosis. However, it was also demonstrated that selec-
tive uptake of HDL-associated lipids occurs independently of HDLholoparticle endocytosis [37]. It is unlikely that the difference of cellular
uptake of DiI- and Cy3-labeled particles is due to major alterations in
HDL surface charge since labeled andunlabeledHDL comigrated on aga-
rose gels (data not shown).
Taken together we demonstrate that ﬂuorescent SL analogs are rap-
idly metabolized in CATH.a cells. BODIPY-SM uptake occurs predomi-
nately via caveolar pathways and is subject to hydrolysis already at
the PM, in line with results reported for NBD-SM [58]. The activity of
aSMase and nSMase at the PMgenerates BODIPY-Cer that reaches intra-
cellular compartments leading to Golgi and ER accumulation [39]. ER/
Golgi localization of BODIPY-Cer results in generation of polar SL that
are secreted into the cellular supernatant. Most of the residual SM re-
sides at the PMwhereas the remaining part is internalized to intracellu-
lar compartments via early endosomes (as shown for NBD-SM; [69]) or
is transported back to the PM via recycling endosomes. Endocytosed
BODIPY-SM is transported to intracellular compartments of SL synthesis
(ER and Golgi) bypassing lysosomal degradation. This is in agreement
with other studies that showed that PYRENE- and NBD-labeled short-
chain SM analogs efﬁciently recycle to the PM after endocytosis and
can directly target the Golgi [38,58]. Our observation that HDL-
associated BODIPY-SM is efﬁciently taken up by neurons might be of
particular importance for SM homeostasis in the CNS.Acknowledgement
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